comparemela.com

Page 8 - John Heymach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Target for Lung Cancer Treatment Resistance After EGFR Inhibitors

The new finding highlights the therapeutic target that could be used to eliminate resistant lung cancer cells remaining after treatment with EGFR TKIs.

BerGenBio ASA: BerGenBio Announces the Establishment of Oncology Scientific Advisory Board

- Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC - BERGEN, Norway, Feb. 2, 2023 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.